Grifols (GRFS) Other financing activities (2011 - 2020)
Grifols (GRFS) reported Other financing activities of $5.3 million for Q1 2020, down 54.36% on a YoY basis from $11.6 million in Q2 2019, and down 52.75% quarter-over-quarter from $11.2 million in Q4 2019.
Grifols (GRFS) Other financing activities (2011 - 2020) Analysis & Trends
Grifols has reported Other financing activities for 9 years, with the latest figure at $5.3 million in Q1 2020.
- For the quarter ending Q1 2020, Other financing activities fell 54.36% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2020 stood at $27.4 million (up 185.1% YoY), and the FY2025 full-year result was $43.1 million, down 22.49% from the prior year.
- Other financing activities for Q1 2020 stood at $5.3 million, down from $11.2 million in the prior quarter.
- The five-year high for Other financing activities was $273.3 million in Q2 2017, with the low at -$103.6 million in Q1 2017.
- Historically, Other financing activities has averaged $29.9 million across 5 years, with a median of $5.3 million in 2020.
- Annual changes were most pronounced in 2016 — Other financing activities slumped 1745.48% — and 2017, when it soared 2902.98%.
- Grifols' Other financing activities stood at $6.1 million in 2016, then surged by 2902.98% to $182.0 million in 2017, then sank by 100.39% to -$700817.4 in 2018, then surged by 1701.54% to $11.2 million in 2019, then plunged by 52.75% to $5.3 million in 2020.
- The last three Other financing activities figures came in at $5.3 million (Q1 2020), $11.2 million (Q4 2019), and $11.6 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.30 Mn |
| Mar 31, 2020 | 5.30 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Dec 31, 2018 | -700,817.41 |
| Dec 31, 2018 | -700,817.41 |
| Jun 30, 2018 | -2.48 Mn |
| Jun 30, 2018 | -2.48 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Jun 30, 2017 | 273.32 Mn |
| Jun 30, 2017 | 273.32 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Dec 31, 2016 | 6.06 Mn |